Project Grant R41NS105304

The National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $818,360 Cooperative Agreement to the University of Southern California (USC) to develop new highly potent and safe Angiotensin AT2 receptor (AT2R) antagonists for the treatment of neuropathic pain. This 4-year project aims to optimize a novel lead series of AT2R antagonists that have demonstrated better potency and...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $6,522,833 Project Grant to The Leland Stanford Junior University to conduct a mechanistic randomized clinical trial investigating the central and peripheral nervous system mechanisms of pain relief induced by peripheral nerve stimulation (PNS) for the treatment of refractory chronic neuropathic pain. The 3-year study, funded under the NIH HEAL Initiative's CFDA 93.279 Drug Abuse and Addiction Research Programs, aims...

This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $400,000 Project Grant to Navega Therapeutics, Inc., a San Diego-based biotechnology company, under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support Navega's research and development efforts to advance novel epigenetic gene therapies targeting the voltage-gated sodium channel NAV1.7 for the treatment of chronic pain. This innovative approach aims to transiently repress NAV1.7...

Regulonix LLC was awarded a $1,258,410 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), to support research under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). Through this one-year award ending August 31, 2022, Regulonix will partner with the University of Arizona to characterize inhibitors of the neuropilin-1 (NRP-1) receptor for potential...

This $453,104 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to explore independent ascending spinal pain circuits that transmit pain signals to the brain. The primary focus is on understanding the role of a newly identified subset of spinal projection neurons expressing the GPR83 neuropeptide receptor, in...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,510,066 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation to conduct a planning study for the development of sigma 2 ligands as novel analgesics for chronic neuropathic pain. The funding will support an interdisciplinary research team to: (1) develop an in-silico library of potential sigma 2 ligand analogs, (2) synthesize and evaluate...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $387,500 to Texas Tech University Health Sciences Center (TTUHSC) for the project "Identification of Novel Lead EphB1/2 Tyrosine Kinase Inhibitors Targeting Peripheral Neuropathic Pain". The objective is to pharmacologically examine whether selective inhibition of the...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $650,079 Project Grant to Northeastern University under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports the development and optimization of novel small-molecule probes targeting the alpha9 nicotinic acetylcholine receptor (α9*-nAChR) subunit, with the goal of exploring its potential for pain management. The 5-year project aims to advance...